SB 1089 tasks the California Health and Human Services Agency (CHHSA) with creating partnerships to produce, procure, or distribute FDA‑registered generic prescription drugs and make them broadly available to state and private purchasers, providers, suppliers, and pharmacies. The statute limits partnerships to products that will lower costs, remedy market failures, or increase access; it requires transparent, rebate‑free pricing and directs CHHSA to consider specific cost components when setting prices.
The bill mandates priority attention to drugs that meaningfully reduce patient or purchaser spending and explicitly requires partnerships to include at least one form of insulin and one GLP‑1/GLP‑1RA offered at production plus dispensing costs if no such low‑cost option exists. CHHSA must consult a named list of state purchasers and industry stakeholders, consider multi‑year volume commitments, and may include governance roles for partner contractors.
Purchasers are not forced to buy from CHHSA partners.
At a Glance
What It Does
The bill requires CHHSA to enter partnerships with FDA‑registered drug manufacturers to produce, procure, or distribute generic drugs when those partnerships can reduce prices, fix market failures, or improve access. It sets pricing criteria (user fees, ANDA costs, rebates, production/contracting costs, amortized R&D and start‑up costs) and mandates transparent prices without non‑federal rebates.
Who It Affects
State purchasers (CalPERS, Medi‑Cal/DHCS, Covered California, state agencies), licensed health plans and insurers, hospitals, pharmacies, generic drug manufacturers, and patients who use insulin, GLP‑1 drugs, and other high‑cost generics. Procurement and pharmacy contracting teams will be directly engaged.
Why It Matters
This statute authorizes direct state intervention into generic supply—shifting California from buyer to active market participant and potential producer partner. It targets supply shortages and high‑cost drugs and could alter pricing dynamics, contracting leverage, and competitive incentives across public and private procurement networks.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 1089 converts CHHSA into an active market player: not merely a purchaser but a partner that can finance, guarantee volume, and coordinate production or procurement of generic drugs. The agency may only pursue partnerships when they demonstrably yield savings, address a market failure (for example, a shortage or lack of competition), or improve patient access.
When CHHSA evaluates a candidate drug it must examine legal, market, policy, and regulatory pathways to determine whether manufacturing or procurement partnerships are viable.
The bill prescribes detailed cost elements CHHSA should use when setting prices, including FDA user fees, acquisition costs for Abbreviated New Drug Applications amortized over five years, mandatory rebates, contracting and production costs (with room for administrative and a reasonable return), and amortized R&D and start‑up costs. Any product sold through these partnerships must be offered at a transparent price and without rebates except those federally required, and CHHSA will prioritize drugs that lower patient costs, increase competition, address shortages, or reduce purchaser spending.SB 1089 singles out insulin and GLP‑1/GLP‑1RA drugs: partnerships must include at least one insulin formulation and at least one GLP‑1 or GLP‑1RA at production plus dispensing costs if no low‑cost option exists in the market.
The statute also directs CHHSA to consider guaranteeing priority state access to these supplies, producing at least four high‑priority drugs for California, and creating a state brand for biosimilar insulin and other generics sold under the program. The agency must consult specified purchaser groups and use state spending and regulator reports to identify priorities.On procurement mechanics, the bill requires CHHSA to weigh multi‑year volume data and, for procurement deals, set minimum advance‑purchase thresholds to support a lower‑cost market entrant.
CHHSA may coordinate with the Statewide Pharmaceutical Program and the California Pharmaceutical Collaborative. Notably, the listed purchasers are not compelled to buy from CHHSA partners, and CHHSA need not consult every stakeholder exhaustively so long as it secures reasonable representation from health plans, insurers, and hospitals.
Partnerships may include governance roles for contractor entities, giving partners operational influence in return for commitments or investments.
The Five Things You Need to Know
CHHSA may form partnerships only with FDA‑registered drug companies or generic manufacturers and only where the partnership produces savings, remedies a market failure, or improves access.
When setting prices CHHSA must consider specific cost components—FDA user fees; ANDA acquisition costs amortized over five years; mandatory rebates; total contracting/production costs allowing a reasonable administrative and rate‑of‑return allowance; and amortized R&D and start‑up costs.
Drugs sold through CHHSA partnerships must have transparent prices and be offered without rebates other than federally required rebates.
Partnerships must include at least one form of insulin and at least one GLP‑1 or GLP‑1RA at production plus dispensing costs if similar low‑cost options do not already exist; CHHSA may guarantee priority state access and create a state brand.
CHHSA must consult specific state purchasers and use regulator reports and state pharmacy spending data to prioritize drugs, but those purchasers are not required to buy from CHHSA partners and CHHSA need not consult every listed entity so long as representation is reasonable.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Authority to form partnerships with FDA‑registered manufacturers
This subsection gives CHHSA explicit authority to enter partnerships that produce, procure, or distribute generic prescription drugs and conditions that authority on the manufacturer being registered with the FDA. Practically, that clears a path for CHHSA to negotiate operational or financial arrangements with contract manufacturers, generic drug firms, or vertically integrated companies that can supply California purchasers and pharmacies.
Eligibility, pricing criteria, and transparent pricing requirement
Subdivision (b) restricts partnerships to cases where they will generate savings, remedy market failures, or improve access. It lists concrete pricing inputs CHHSA must consider (FDA user fees; ANDA acquisition amortized over five years; mandatory rebates; contracting and production costs, including a reasonable return; R&D and start‑up costs amortized over five years). It also imposes a transparency rule: drugs must be sold at a transparent, rebate‑free price except for federally required rebates—this is a functional change to how prices are presented and may disrupt existing rebate‑based agreements with PBMs and plans.
Priority drugs, insulin and GLP‑1 requirements, and state branding
This subsection drives prioritization. CHHSA must use regulator reports and state spending data to prioritize drugs and the partnerships must include at least one insulin product and one GLP‑1/GLP‑1RA offered at production plus dispensing costs where no such low‑cost option exists. The provision contemplates guarantees for priority state access, production of multiple high‑priority drugs for California, and allows CHHSA to create a state brand for biosimilar insulin and other generics—tools intended to secure supply and create a recognisable low‑cost product line.
Mandatory stakeholder consultation list
CHHSA must consult specified public purchasers and stakeholder groups—CalPERS, DHCS (Medi‑Cal), Covered California, the Department of Public Health, DGS, CDCR, licensed health plans, insurers, and hospitals—to develop the drug list. Requiring these consultations builds forward demand visibility and aligns the program with the needs of large purchasers, but the text allows CHHSA to use reasonable representation rather than exhaustive outreach to every single entity listed.
Volume commitments and procurement thresholds
For manufacturing or procurement partnerships where volume matters to achieving low prices, CHHSA must analyze multiyear usage and may set minimum purchase thresholds for partners’ expected volumes over a target period. The agency can coordinate with the Statewide Pharmaceutical Program and California Pharmaceutical Collaborative to structure advance commitments that underwrite lower unit prices and production planning.
Purchasing discretion and governance participation
These subsections make three operational points: listed purchasers are not compelled to buy from CHHSA partners; CHHSA need not consult every listed stakeholder so long as consultation includes reasonable representation; and partnerships may include partner representation in contractor governance. Together these clauses preserve purchaser freedom while allowing CHHSA to offer governance or operational roles to partners in exchange for commitments.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients using insulin, GLP‑1s, and other high‑cost generics — the bill targets lower, transparent prices and increased supply for chronic‑condition medicines that often carry major out‑of‑pocket burdens.
- Public purchasers (CalPERS, Medi‑Cal/DHCS, Covered California, state agencies) — potential for lower procurement costs, priority supply guarantees, and reduced exposure to price spikes or shortages.
- Hospitals, pharmacies, and providers — clearer pricing and alternative supply channels reduce uncertainty from shortages and rebate opacity, and may simplify contracting for commonly used generics.
- State procurement programs and policy teams — CHHSA gains tools (volume guarantees, state branding, governance leverage) to secure supply and plan budgets more predictably.
- Some generic manufacturers — those willing to accept lower margins in exchange for guaranteed multi‑year volume commitments and governance input may win stable contracts.
Who Bears the Cost
- Private generic manufacturers that currently earn higher margins through existing channels — they may face downward price pressure or lose volume to state‑backed partners.
- CHHSA and the State — the agency must absorb program design, contracting, oversight, and potential financial risk if guaranteed volume commitments or production arrangements fail or require subsidies.
- Health plans, PBMs, and manufacturers that rely on rebate architectures — the prohibition on non‑federal rebates will disrupt existing commercial arrangements and could shift where discounts are negotiated or how list and net prices are structured.
- Smaller contract manufacturers or biosimilar developers — upfront ANDA or development costs and compliance with state governance expectations may be more burdensome without clear funding support.
- Purchasers that opt out — entities that decline to buy from CHHSA partners may miss savings but still bear administrative costs to evaluate the new options.
Key Issues
The Core Tension
The central tension is between using direct, state‑backed partnerships to secure low, transparent prices and guaranteed supply for critical generics, and the risk that such intervention disrupts existing commercial rebate and procurement systems, imposes financial and operational risk on the state, and fails to bridge regulatory and manufacturing gaps—especially for biologics—without heavy public investment.
SB 1089 leaves several implementation choices open that could meaningfully change outcomes. The bill prescribes cost inputs for pricing but does not define ‘‘reasonable rate‑of‑return,’’ ‘‘production and dispensing costs,’’ or how mandatory federal rebates (for example, Medicaid) interact with the rebate‑free retail price requirement.
Those gaps give CHHSA technical discretion that will determine partner margins and the programme’s commercial attractiveness.
The bill treats GLP‑1s and insulin equivalently as generics to be produced or procured, but biologics and biosimilars (including many GLP‑1 compounds and modern insulin formulations) involve different regulatory, manufacturing, and quality control requirements than small‑molecule generics. Converting the statutory intent into on‑the‑ground production could require complex biosimilar pathways, large capital investments, or partnerships with experienced biologics manufacturers.
Additionally, the move away from rebate‑driven pricing could trigger strategic responses from PBMs and manufacturers that reallocate discounts, potentially shifting costs to other payers.
Finally, setting multi‑year volume guarantees creates risk: overcommitment can leave the state on the hook for unused purchases, while undercommitment may fail to lower prices. The law allows governance roles for contractors, which helps attract partners but raises questions about conflict of interest, procurement integrity, and oversight.
Answering these operational questions will determine whether the bill reduces prices sustainably or simply reallocates costs and market distortions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.